{
    "clinical_study": {
        "@rank": "127866", 
        "arm_group": [
            {
                "arm_group_label": "ASP2408 low dosing frequency", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP2408 high dosing frequency", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo low dosing frequency", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo high dosing frequency", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of\n      two dosing regimens of multiple, subcutaneous (sc) injections of ASP2408 in patients with\n      Rheumatoid Arthritis (RA) on Methotrexate (MTX) and to evaluate the pharmacodynamics (PD) of\n      ASP2408."
        }, 
        "brief_title": "A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Rheumatoid Arthritis", 
            "Pharmacokinetics of ASP2408"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an ascending dose frequency study. There are two cohorts of active and placebo\n      patients.  The first cohort is dosed every 4 weeks for a total of 3 doses. The second cohort\n      is dosed every two weeks for a total of 3 doses."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject weighs at least 50 kg.\n\n          -  Subject has a body mass index (BMI) of \u2264 35 kg/m2.\n\n          -  Subject's 12-lead electrocardiogram (ECG) results are normal at Screening and Day 1\n             prior to study drug dosing or, if abnormal, the abnormality is not clinically\n             significant as determined by the Investigator.\n\n          -  Subject has Rheumatoid Arthritis (RA) that was diagnosed according to the 1987\n             revised criteria of the American College of Rheumatology (ACR) \u2265 6 months prior to\n             Screening.\n\n          -  Subject meets the ACR 1991 revised criteria for Global Functional Status in RA, Class\n             I, II or III at Screening.\n\n          -  Subject MUST be on concomitant methotrexate (MTX):\n\n               -  for \u2265 3 months prior to Day 1, AND\n\n               -  at a stable dose (10 - 25 mg/week) for \u2265 28 days prior to Day 1 and throughout\n                  the study.\n\n          -  Subject's other related medications taken for the treatment of RA at the time of\n             Screening must meet the noted stability requirements and remain on a stable regimen,\n             as follows:\n\n               -  Non-steroidal anti-inflammatory drugs (NSAIDs), selective cyclooxy-genase-2\n                  (COX-2) inhibitors, oral corticosteroids (\u2264 10 mg of prednisone, or equivalent,\n                  daily) or low dose opioids (\u2264 30 mg of oral morphine, or equivalent, daily) must\n                  be stable for \u2265 28 days prior to Screening and remain so throughout the\n                  Treatment and Observation Period.\n\n          -  Hydroxychloroquine (Plaquenil\u00ae) and sulfasalazine must have started \u2265 2 months, and\n             be stable for \u2265 28 days, prior to Day 1.\n\n        Exclusion Criteria:\n\n          -  Subject has an ongoing infection or has had an infection requiring intravenous\n             antibiotics within 1 month prior to Day 1.\n\n          -  Subject has a past history of serious opportunistic infection.\n\n          -  Subject has a positive Mantoux tuberculin skin or QuantiFERON-TB Gold test within 90\n             days of, or at Screening, and has not completed an adequate course of antimicrobial\n             therapy per CDC guidelines.\n\n          -  Subject received any live or live-attenuated vaccine within 30 days prior to Day 1.\n\n          -  Subject received any of the following:\n\n               -  Anakinra (Kineret\u00ae), etanercept (Enbrel\u00ae), or adalimumab (Humira\u00ae) within 60\n                  days prior to Day 1.\n\n               -  Rituximab (Rituxan\u00ae) or any other anti-CD20 antibody within 180 days prior to\n                  Day 1.\n\n               -  Leflunomide (Arava\u00ae) within 60 days prior to drug dosing on Day 1, unless the\n                  subject has undergone cholestyramine washout at least 30 days prior to Day 1.\n\n               -  Oral or injectable gold, azathioprine, penicillamine, cyclosporine, or\n                  tacrolimus within 30 days prior to Day 1.\n\n               -  Cyclophosphamide within 180 days prior to Day 1.\n\n          -  Subject has received any CTLA4-Ig molecule (including, but not limited to abatacept\n             [Orencia\u00ae] and belatacept [Nulojix]).\n\n          -  Subject has participated in a previous clinical study with treatment  with ASP2408 or\n             ASP2409 or has participated in another dose cohort of the current trial.\n\n          -  Subject has previously participated in any interventional clinical study, or has\n             received an experimental agent within 56 days or 5 half-lives, whichever is longer,\n             prior to Day 1.\n\n          -  Subject has a history of prolonged QT syndrome."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052375", 
            "org_study_id": "2408-CL-0201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ASP2408 low dosing frequency", 
                    "ASP2408 high dosing frequency"
                ], 
                "description": "subcutaneous injection", 
                "intervention_name": "ASP2408", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo low dosing frequency", 
                    "Placebo high dosing frequency"
                ], 
                "description": "subcutaneous injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "ASP2408", 
            "methotrexate"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36207"
                    }, 
                    "name": "Pinnacle Research Group, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Altoona Center for Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "Metroplex Clinical Research Center, LLC"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development, Inc.", 
            "last_name": "Senior Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area Under the Concentration-Time curve for a dosing interval (AUCtau)", 
                "measure": "Pharmacokinetic parameter of ASP2408: AUCtau", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, 4, 5, 6, 8, 10, 15, 22, 36, 38, 43, 50, 57, 66, 71, 78, 85, 113, 141"
            }, 
            {
                "description": "Maximum Concentration (Cmax)", 
                "measure": "Pharmacokinetic parameter of ASP2408: Cmax", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, 4, 5, 6, 8, 10, 15, 22, 36, 38, 43, 50, 57, 66, 71, 78, 85, 113, 141"
            }, 
            {
                "description": "Time to Attain Cmax (Tmax)", 
                "measure": "Pharmacokinetic parameter of ASP2408: Tmax", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2 ,3, 4, 5, 6, 8, 10, 15, 22, 36, 38, 43, 50, 57, 66, 71, 78, 85, 113, 141"
            }, 
            {
                "description": "Trough Concentration (Ctrough)", 
                "measure": "Pharmacokinetic parameter of ASP2408: Ctrough", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, 4, 5, 6, 8, 10, 15, 22, 36, 38, 43, 50, 57, 66, 71, 78, 85, 113, 141"
            }, 
            {
                "measure": "Safety assessed by adverse events (AEs), laboratory tests, electrocardiograms (ECGs), physical examinations, pulse oximetry, vital signs and Anti-ASP2408 antibody (ADA) formulation", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052375"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Apparent Terminal Elimination Half-life (t1/2), Volume of distribution (Vz/F), Apparent Body Clearance (CL/F)", 
                "measure": "Composite of pharmacokinetics of ASP2408: t1/2, Vz/F, CL/F,", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, 4, 5, 6, 8, 10, 15, 22, 36, 38, 43, 50, 57, 66, 71, 78, 85, 113, 141"
            }, 
            {
                "description": "Cluster of Differentiation 86, a co-stimulatory ligand on antigen-presenting cells; alternate notation for B7.2 (CD86)", 
                "measure": "Pharmacodynamic parameter of ASP2408: CD86 receptor occupancy", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3, 4, 5, 6, 8, 10, 15, 22,36, 38, 43, 50, 57, 66, 71, 72, 78, 85,113, 141"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}